UNSPSC 51451903: Piperamide

This classification denotes an antihelminthic agent with the molecular formula C17H28N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83B7UZO20C, chemically known as N-[4-[4-[3-(dimethylamino)propyl]piperazin-1-yl]phenyl]acetamide but generally known as piperamide, which bears US NIH Compound Identifier 14739. Most nations schedule piperamide under HS 29335995 and SITC 51576. As of Q4 2014, PIPERAMIDE remains the US FDA Preferred Term for this commodity.

Piperamide bears US NLM identifiers UMLS ID C2698815 and NCI Concept Code C75123. SMILES: CC(=O)NC1=CC=C(C=C1)N2CCN(CC2)CCCN(C)C.

UNSPSC 51451903 Piperamide, a Commodity code, shows significant misalignment between its nominal classification and the recent state and local opportunities tagged under it. The four recent solicitations posted between January and June 2026 involve naloxone procurement (opioid overdose reversal), generic pharmaceuticals and OTC products distributed through wholesalers, direct-to-manufacturer prescription programs, and emergency medical supplies for fire departments — none of which are piperamide products or chemical intermediates. The code's application to naloxone, pharmaceutical benefit management, and medical consumables suggests state and local procurement offices are using this Commodity code to tag pharmaceutical and medical-supply buys more broadly, rather than for piperamide specifically.

The issuing bodies span state health agencies (Texas HHS), county health departments (Seminole County, Florida), municipal fire services (City of Tampa), and multistate cooperative purchasing organizations (Minnesota MMCAP serving multiple states including Oregon). Recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the City of Tampa's IFB for 169 line items of emergency medical and first aid supplies for its Fire Department Rescue Division with an estimated contract value of $700,000.00 (due March 13, 2026), Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (due March 26, 2026), and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026). Geographic activity centers on Florida, Texas, and Minnesota, with the MMCAP cooperative extending into Oregon. Because the code's recent activity does not reflect genuine piperamide procurement, this code warrants limited pursuit unless your firm supplies pharmaceutical products, naloxone systems, or medical consumables to state and local health or emergency-response agencies through the wholesale distribution or direct-to-agency channels these solicitations demonstrate.